Do Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Stock to Rise After It Has Fallen -66.86% in a Month?

Analysts who follow Galmed Pharmaceuticals Ltd (GLMD) on average expect it to increase 1226.73% over the next twelve months. Those same analysts give the stock an average rating of Hold. That average rating earns GLMD an Analyst Ranking of 5, which means it ranks higher than 5 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating GLMD a Hold today. Find out what this means to you and get the rest of the rankings on GLMD!

See Full GLMD Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Galmed Pharmaceuticals Ltd Stock Today?

Galmed Pharmaceuticals Ltd (GLMD) stock has fallen -8.87% while the S&P 500 has risen 0.17% as of 1:00 PM on Friday, Jul 21. GLMD is down -$0.11 from the previous closing price of $1.24 on volume of 544,763 shares. Over the past year the S&P 500 is higher by 13.60% while GLMD is down -87.29%. GLMD lost -$8.08 per share the over the last 12 months. Click Here to get the full Stock Report for Galmed Pharmaceuticals Ltd stock.